Sustained HPV vaccine coverage key to stronger cervical cancer prevention

Human papillomavirus (HPV) remains one of the most widespread sexually transmitted infections worldwide, and persistent infection with high-risk HPV types is a major driver of cervical cancer. Although many HPV infections clear naturally, infections that persist can lead to precancerous lesions and, over time, cervical cancer. This makes vaccination one of the most important prevention tools available to public health systems.

New research has found that an optimized female-only HPV vaccination strategy can substantially reduce persistent infections and cervical cancer risk in settings where full gender-neutral vaccination is difficult to achieve. Published in Mathematics, the study shows that vaccinating girls can also provide indirect protection to males by lowering overall virus transmission in the population.

The study, titled "Optimizing HPV Vaccination Strategy: An Optimal Control Problem," uses Tunisia as a country-specific example to built a gender-stratified dynamic transmission model to examine how bivalent HPV vaccination can reduce infection, persistence and cervical cancer risk under different levels of vaccine availability, coverage and cost constraints.

HPV prevention depends on matching vaccine strategy with real-world constraints

According to the study, HPV types 16 and 18 are responsible for about 70 percent of cervical cancer cases worldwide, making them the main targets of existing HPV vaccines. Other high-risk types, including 31, 33, 45, 52 and 58, account for a significant share of remaining cervical cancer cases. This means that effective prevention must consider both the vaccine-targeted types and the high-risk types circulating in each country.

The study addresses a major policy challenge for low- and middle-income countries: how to design an effective HPV vaccination program when vaccine supply, funding, public acceptance and delivery capacity are limited. In high-income settings, many governments have expanded HPV vaccination to both girls and boys. Gender-neutral vaccination can reduce virus circulation more broadly and strengthen population-wide protection. But in countries with tighter health budgets and weaker delivery capacity, policymakers often prioritize girls because the most direct disease burden is cervical cancer.

The researchers tested that approach through a mathematical model that separates the population by sex and infection status. Females were grouped as susceptible, vaccinated, infected, recovered, persistently infected or cancer cases, while males were grouped as susceptible, infected or recovered. The model also separated HPV into two strain groups: one representing HPV 16 and 18, which are directly targeted by the bivalent vaccine, and another representing high-risk types not directly targeted by the vaccine but potentially affected through cross-protection.

Tunisia was used as the country example because its HPV profile and resource constraints reflect the kind of decision many health systems face. The country has adopted a female-only vaccination approach, and the bivalent vaccine has been identified as a practical option in the national context. Tunisian data also show that high-risk HPV types outside the direct vaccine target group are important in local circulation. This makes the country a useful example for studying whether bivalent vaccination can still reduce broader HPV transmission through cross-protection.

The model incorporated vaccine efficacy, vaccine coverage, natural recovery, persistent infection, progression to cancer, sex-specific transmission and mortality. It also estimated the basic reproduction number for each strain group, a measure that shows whether infection can persist in a population. The results showed that vaccination directly reduces the transmission potential of HPV 16 and 18, while its effect on other high-risk types depends heavily on cross-protection.

HPV vaccination strategies cannot be judged only by whether a vaccine directly targets the most visible genotypes. In many countries, the value of a vaccine also depends on how much protection it provides against related high-risk types that contribute to local disease burden. This is especially important where switching to more expensive vaccines or universal gender-neutral programs may not be feasible.

Sustained coverage and cross-protection are key to reducing cervical cancer risk

The study found that vaccine coverage, vaccine efficacy and cross-protection are the strongest drivers of HPV transmission reduction. For HPV 16 and 18, higher coverage and stronger vaccine efficacy sharply lowered the basic reproduction number. In the model, strong vaccination coverage was able to push the targeted strain group below the threshold needed for sustained transmission.

The second strain group, made up of high-risk types not directly targeted by the bivalent vaccine, was harder to suppress. Its control depended mainly on cross-protection. This means that even very high vaccine coverage may not fully eliminate non-targeted high-risk strains unless the vaccine provides meaningful indirect protection against them.

Direct vaccine protection can reduce the most oncogenic HPV types, while cross-protection can broaden the benefit of vaccination in settings where other high-risk types are common. A vaccine strategy that appears limited on paper may still deliver wider population benefits if it reduces susceptibility to non-targeted genotypes.

The researchers then used an optimal control framework to identify the best vaccination approach under different conditions. The goal was to reduce persistent infections and cervical cancer cases while also limiting vaccination effort. This design reflects clinical reality. Most HPV infections clear naturally, so the most important prevention target is not every infection but persistent infection, which is the pathway toward cervical cancer.

Three vaccination scenarios were compared. The first represented an ideal setting with full vaccine availability, no cost constraint and maximum coverage. The second allowed full maximum coverage but added a moderate cost for vaccination effort, representing a health system that can still vaccinate widely but must account for resource limits. The third represented a more constrained setting, with higher vaccination cost and a maximum coverage ceiling of 80 percent.

The first two scenarios produced very similar reductions in persistent infections and cervical cancer. This suggests that a moderately constrained vaccination program can still deliver nearly the same health impact as an ideal program if high coverage is sustained. The second scenario emerged as the best balance between public health benefit and vaccination effort.

The third scenario produced smaller reductions, as expected, because it imposed tighter limits on coverage and cost. However, it still achieved meaningful disease reduction. Persistent infection levels eventually stabilized, and cancer cases continued to decline over time. This delayed benefit reflects the long natural history of cervical cancer: vaccination prevents infections today, but the full impact on cancer burden appears years later.

The model also showed indirect benefits for males. Because only girls were vaccinated in the scenarios, reductions in male infections came from lower transmission among female partners. Strong female vaccination reduced male infection risk substantially, showing that female-only vaccination can generate herd effects even without direct vaccination of boys.

This does not mean male vaccination is unnecessary in every setting. The authors note that complete eradication is more likely when male vaccination is added, a conclusion consistent with other modeling work. But the study shows that where gender-neutral vaccination is not affordable or logistically possible, prioritizing girls can still provide major population-level protection.

The findings are relevant beyond Tunisia. Many health systems face the same tension between ideal vaccination strategy and practical capacity. The study shows that mathematical modeling can help countries identify realistic programs that still achieve strong public health outcomes.

Public health success will depend on uptake, delivery and long-term planning

Optimized female-only HPV vaccination can be a powerful cervical cancer prevention strategy in resource-limited settings. It can reduce persistent infection among women, lower future cancer risk and indirectly reduce infection among men. But the scale of impact depends on sustained coverage and public acceptance.

This is where real-world implementation becomes critical. A vaccination strategy can be mathematically strong but fail in practice if eligible girls are not reached, if parents refuse vaccination, if health systems cannot deliver doses consistently or if public communication is weak. Vaccine hesitancy, limited access and uneven school-based delivery can sharply reduce the benefits predicted by models.

Using Tunisia as an example, the study notes that even an 80 percent maximum coverage scenario may be ambitious where HPV vaccine uptake remains low and hesitancy is widespread. This point applies to many countries considering or expanding HPV vaccination. The main challenge is often not whether vaccination works, but whether health authorities can build enough trust, access and continuity to sustain high uptake across adolescent cohorts.

The results also highlight the need for country-specific vaccine planning. HPV genotype distributions vary across regions. A vaccine that is cost-effective in one setting may need to be assessed differently in another, depending on local strain circulation, cancer burden, vaccine price, delivery systems and public acceptance. The study's use of Tunisia as an example shows how national data can be built into models to guide policy choices.

The study supports three practical lessons for policymakers:

• Female-only vaccination remains a strong option where resources are limited, especially when cervical cancer prevention is the main objective.
• Cross-protection matters and should be included in vaccine planning, particularly in countries where non-targeted high-risk HPV types are common.
• Sustained coverage is essential. Shortfalls in uptake can weaken herd immunity and allow transmission to continue.

The study also reinforces the value of long-term thinking in cervical cancer prevention. HPV vaccination is not a quick-impact intervention in the same way as treatment for an acute outbreak. Its benefits accumulate over time by preventing infections that could later become persistent and progress to cancer. This makes early adolescent vaccination especially important, because protection is strongest before exposure to HPV.

Health systems also need continued surveillance after vaccination begins. Monitoring HPV type distribution, persistent infection trends and cervical cancer outcomes can help detect whether non-targeted strains remain a concern and whether vaccine policy needs adjustment. Modeling can guide initial strategy, but real-world data are needed to refine it over time.

The findings may also support broader debates about equity in cancer prevention. Cervical cancer disproportionately affects women in settings where screening, vaccination and treatment access are limited. A well-designed HPV vaccination strategy can reduce that burden before disease develops. But if coverage is uneven, the benefits may concentrate among better-served groups while vulnerable populations remain exposed.